Effectiveness of dopamine in patients with cardiogenic shock

      This paper is only available as a PDF. To read, Please Download here.
      Dopamine was evaluated in 24 patients with cardiogenic shock of various causes (systolic blood pressure less than 90 mm Hg or 60 mm Hg below the patient's usual level as recorded by intraarterial needle, average urinary flow less than 20 ml/hour without diuretic therapy). Dopamine was not given until hypovolemia was corrected, as judged by left ventricular filling pressure (18 patients) or central venous pressure. Twelve patients survived the shock episode, 5 of whom are alive 7 to 24 months later. The 12 survivors of shock included all 6 patients (100 percent) with shock after open heart surgery; 3 of 10 (30 percent) with acute myocardial infarction; 1 of 4 (25 percent) with severe heart failure; and 2 of 4 (50 percent) with shock after noncardiac surgery. Seven patients, including 6 of the 12 survivors, received no pressor agent other than dopamine. In 12 nonsurvivors hourly urinary flow increased from 10 ± 2.3 (standard error of the mean) to a maximum of 101 ± 55 ml/hour (not significant), but 8 of these patients had virtually no change in urinary flow during dopamine therapy. In the 12 survivors, there was a larger increment in urinary flow [from 25.7 ± 11 to 250 ± 59 ml/hour (P <0.001)]. In survivors, left ventricular filling pressure decreased during dopamine infusion from 27 ± 2.4 to 18 ± 2.3 mm Hg (P <0.05); in nonsurvivors it was unchanged (27 mm Hg). Survivors had a small but significant decrease in heart rate and a significant increase in mean arterial pressure compared with values in non-survivors. In survivors, maintenance doses of dopamine averaged 9.1 μg/kg per min. In 3 of 4 patients receiving intraaortic balloon counter-pulsation, 2 of whom survived, dopamine augmented urinary flow from an average of 20 to 208 ml/hour. We conclude that dopamine is useful, either alone or in conjunction with other pressor agents, for the treatment of cardiogenic shock, particularly in patients with diminished urinary flow and hypotension after cardiopulmonary bypass.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • MacCannell KL
        • McNay JL
        • Meyer MB
        • et al.
        Dopamine in the treatment of hypotension and shock.
        New Eng J Med. 1966; 275: 1389-1398
        • Talley RC
        • Goldberg LI
        • Johnson CE
        • et al.
        A hemodynamic comparison of dopamine and isoproterenol in patients in shock.
        Circulation. 1969; 39: 361-378
        • Loeb HS
        • Winslow EBJ
        • Rahimtoola SH
        • et al.
        Acute hemodynamic effects of dopamine in patients with shock.
        Circulation. 1971; 44: 163-173
        • Rosenblum R
        • Frieden J
        Intravenous dopamine in the treatment of myocardial dysfunction after open-heart surgery.
        Amer Heart J. 1972; 83: 743-748
        • Swan HJC
        • Ganz W
        • Forrester JS
        • et al.
        Catheterization of the heart in man with use of a flow directed balloon-tipped catheter.
        New Eng J Med. 1970; 283: 447-451
        • Rosenblum R
        • Tai AR
        • Lawson D
        Dopamine in man: cardiorenal hemodynamics in normotensive patients with heart disease.
        J Pharmacol Exp Ther. 1972; 183: 256-263
        • Carvalho M
        • Vyden JK
        • Bernstein H
        • et al.
        Hemodynamic effects of 3-hydroxytyramine (dopamine) in experimentally induced shock.
        Amer J Cardiol. 1969; 23: 217-223
        • Tristani FE
        • Cohn JN
        Studies in clinical shock and hypotension. VII. Renal hemodynamics before and during treatment.
        Circulation. 1970; 42: 839-851
        • Lipp H
        • Falicov RE
        • Resnekov L
        • et al.
        The effects of dopamine on depressed myocardial function following coronary embolization in the closed-chest dog.
        Amer Heart J. 1972; 84: 208-214
        • Yeh BK
        • McNay JL
        • Goldberg LI
        Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific receptor.
        J Pharmacol Exp Ther. 1969; 168: 303-309
        • Schuelke DM
        • Mark AL
        • Schmid PG
        • et al.
        Coronary vasodilatation produced by dopamine after adrenergic blockade.
        J Pharmacol Exp Ther. 1971; 176: 320-327
        • Nayler WG
        • McInnes I
        • Stone J
        • et al.
        Effect of dopamine on coronary vascular resistance and myocardial function.
        Cardiovasc Res. 1971; 5: 161-168
        • Goldberg LI
        Cardiovascular and renal actions of dopamine: potential clinical applications.
        Pharmacol Rev. 1972; 24: 1-29
        • Wintroub BU
        • Schroeder JS
        • Schroll M
        • et al.
        Hemodynamic response to dopamine in experimental myocardial infarction.
        Amer J Physiol. 1969; 217: 1716-1720
        • Corday E
        • Swan HJC
        • Lang T
        • et al.
        Physiologic principles in the application of circulatory assist for the failing heart.
        Amer J Cardiol. 1970; 26: 595-602